【Abstract】Objective To evaluate effect of artificial liver support system (ALSS) in liver failure and liver transplantation.Methods Forty-four patients with liver failure (including 12 undergoing liver transplantation) were treated with MARS or plasma exchange. The changes of toxic substances and cytokines in blood were detected before and after treatment. Results ALSS therapy achieved a remarkable improvement in clinical symptoms and physical signs. After ALSS treatment, there was a significant decrease in total bilirubin, total bile acid, alanine aminotransferase, creatinine, urea nitrogen, blood ammonia and endotoxin levels(P＜0.05); the levels of serum NO, TNF-α, IL-4 and IL-6 were significantly decreased(P＜0.05); there was no statistical change in erythrocytes, leukocytes and platelets. The survival rate of 30 liver failure patients caused by severe hepatitis B was 60.0%(18/30). Six patients with acute liver failure were successfully performed liver transplantation. Two patients in 6 with acute liver failure after liver transplantation survived. One patient in 2 with acute liver failure after pancreatoduodenectomy survived. Conclusion ALSS plays a positive role in treatment of liver failure by removing blood toxins, NO and cytokines. ALSS also plays a substitute role for liver failure patients who are waiting for liver transplantation.
目的探索乙型肝炎DNA阳性的终末期肝病患者肝移植前快速转阴及肝移植术后复发的防治。方法4例乙型肝炎两对半小三阳、HBVDNA(-)的患者术前开始联合口服拉米夫定(lamivudine) 及泛昔洛韦, 术后3个月内治疗同前, 3个月后仅口服拉米夫定维持至今； 2例乙型肝炎两对半大三阳、HBVDNA(+)的患者, 术前除口服拉米夫定及泛昔洛韦外, 同时肌注乙肝免疫球蛋白共14 d,肝移植术中无肝期快速静脉滴注15 000 u静脉用乙肝免疫球蛋白，术后3个月内联合口服拉米夫定及泛昔洛韦, 术后3个月内治疗同前, 3个月后仅口服拉米夫定维持至今。结果1例患者术后第19天死于肺部霉菌感染,1例患者第49天死于肝动脉及门静脉栓塞; 4例患者长期存活, 生存时间最长的患者已接近3年,术后全部患者均未发现有乙型肝炎复发。结论拉米夫定、乙肝免疫球蛋白及泛昔洛韦联合使用可使乙型肝炎DNA阳性的终末期肝病患者在肝移植前快速转阴，并能预防乙肝复发。